Eli Lilly and Company

WSE:LILY Stock Report

Market Cap: zł4.1t

Eli Lilly Valuation

Is LILY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Future Cash Flow Value

  • Significantly Below Future Cash Flow Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Future Cash Flow Value

What is the Fair Price of LILY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Ultimate guide to DCF valuation for stock investing

Learn how to determine fair value like the best investors in the world.

Below Future Cash Flow Value: LILY (PLN4522) is trading below our estimate of future cash flow value (PLN5485.64)

Significantly Below Future Cash Flow Value: LILY is trading below future cash flow value, but not by a significant amount.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for LILY?

Key metric: As LILY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for LILY. This is calculated by dividing LILY's market cap by their current earnings.
What is LILY's PE Ratio?
PE Ratio42.8x
EarningsUS$25.28b
Market CapUS$1.08t

Price to Earnings Ratio vs Peers

How does LILY's PE Ratio compare to its peers?

The above table shows the PE ratio for LILY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average29.1x
JNJ Johnson & Johnson
30.1x8.34%US$633.2b
AZN AstraZeneca
28.8x13.37%UK£224.2b
NOVN Novartis
21.5x9.68%CHF 234.2b
MRK Merck
35.8x19.41%US$320.0b
LILY Eli Lilly
42.8x16.20%zł1.1t

Price-To-Earnings vs Peers: LILY is expensive based on its Price-To-Earnings Ratio (42.8x) compared to the peer average (29.1x).

Historical Price to Earnings Ratio

Historical Price to Earnings Ratio compares a stock's price to its earnings over time. Higher ratios indicate that investors are willing to pay more for the stock.

Fetching historical data

Price to Earnings Ratio vs Industry

How does LILY's PE Ratio compare vs other companies in the European Pharmaceuticals Industry?

3 CompaniesPrice / EarningsEstimated GrowthMarket Cap
LILY 42.8xIndustry Avg. 21.5xNo. of Companies10PE020406080100+
3 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: LILY is expensive based on its Price-To-Earnings Ratio (42.8x) compared to the European Pharmaceuticals industry average (21.9x).

Price to Earnings Ratio vs Fair Ratio

What is LILY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

LILY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio42.8x
Fair PE Ration/a

Price-To-Earnings vs Fair Ratio: Insufficient data to calculate LILY's Price-To-Earnings Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst LILY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentzł4,522.00
zł4,603.08
+1.79%
12.48%zł5,657.70zł3,206.03n/a28
Jun ’27zł4,078.50
zł4,425.29
+8.50%
12.60%zł5,462.85zł3,095.62n/a29
May ’27zł3,151.50
zł4,354.27
+38.16%
12.55%zł5,433.00zł3,078.70n/a29
Apr ’27n/a
zł4,473.62
0%
12.62%zł5,549.45zł3,144.69n/a29
Mar ’27n/a
zł4,338.98
0%
11.37%zł5,359.65zł3,108.60n/a29
Feb ’27n/a
zł4,072.68
0%
13.62%zł5,329.35zł2,735.73n/a27
Jan ’27n/a
zł3,914.07
0%
16.19%zł5,370.45zł2,756.83n/a27
Dec ’26n/a
zł3,777.01
0%
17.08%zł5,466.30zł2,806.03n/a27
Nov ’26n/a
zł3,395.38
0%
13.58%zł4,395.03zł2,585.31n/a27
Oct ’26n/a
zł3,224.44
0%
14.84%zł4,320.30zł2,359.83n/a26
Sep ’26n/a
zł3,237.68
0%
15.43%zł4,336.24zł2,368.54n/a27
Aug ’26n/a
zł3,532.89
0%
14.37%zł4,394.55zł2,400.39n/a27
Jul ’26n/a
zł3,449.10
0%
15.01%zł4,311.49zł2,355.02zł4,585.5027
Jun ’26n/a
zł3,575.34
0%
15.09%zł4,453.69zł2,432.69zł4,078.5027
May ’26n/a
zł3,736.48
0%
12.76%zł4,513.55zł2,465.39zł3,151.5026
Apr ’26n/a
zł3,917.70
0%
11.88%zł4,613.75zł2,403.80n/a26
Mar ’26n/a
zł4,027.24
0%
12.84%zł4,812.36zł2,507.28n/a26
Feb ’26n/a
zł3,966.16
0%
14.99%zł4,839.37zł2,358.69n/a26
Jan ’26n/a
zł4,031.24
0%
15.07%zł5,120.75zł2,376.03n/a27
Dec ’25n/a
zł4,030.05
0%
14.86%zł5,074.00zł2,354.34n/a27
Nov ’25n/a
zł4,048.97
0%
13.94%zł5,031.75zł2,334.73n/a27
Oct ’25n/a
zł3,857.15
0%
13.87%zł4,456.14zł2,247.44n/a25
Sep ’25n/a
zł3,823.44
0%
13.93%zł4,455.68zł2,247.21n/a25
Aug ’25n/a
zł3,663.65
0%
16.35%zł4,453.03zł2,152.76n/a26
Jul ’25n/a
zł3,501.21
0%
14.02%zł4,148.20zł2,175.82n/a25
zł4.55k
Fair Value
0.5% undervalued intrinsic discount
28
Number of Analysts

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/07/04 14:34
End of Day Share Price 2026/07/02 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Eli Lilly and Company is covered by 52 analysts. 27 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Emily FieldBarclays
Kerry HolfordBerenberg